5,937 Shares in Humana Inc. (NYSE:HUM) Purchased by AGP Franklin LLC

AGP Franklin LLC purchased a new stake in Humana Inc. (NYSE:HUM - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 5,937 shares of the insurance provider's stock, valued at approximately $1,506,000.

Other institutional investors also recently bought and sold shares of the company. FPC Investment Advisory Inc. acquired a new position in Humana during the 4th quarter valued at approximately $27,000. Centricity Wealth Management LLC purchased a new stake in Humana during the 4th quarter valued at about $30,000. LFA Lugano Financial Advisors SA increased its holdings in shares of Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after purchasing an additional 45 shares during the period. OFI Invest Asset Management acquired a new stake in shares of Humana during the fourth quarter worth about $33,000. Finally, Atwood & Palmer Inc. increased its holdings in Humana by 64.5% in the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock worth $39,000 after buying an additional 60 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Trading Down 7.4 %

NYSE HUM traded down $21.20 during mid-day trading on Friday, hitting $264.41. The company's stock had a trading volume of 3,670,273 shares, compared to its average volume of 1,757,258. The firm has a market capitalization of $31.91 billion, a P/E ratio of 26.57, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The stock's fifty day simple moving average is $265.90 and its two-hundred day simple moving average is $269.86.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Research analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.34%. Humana's payout ratio is 35.58%.

Analyst Ratings Changes

HUM has been the subject of several recent research reports. Royal Bank of Canada reissued an "outperform" rating and set a $283.00 target price on shares of Humana in a report on Wednesday, February 12th. Truist Financial lifted their price target on Humana from $290.00 to $325.00 and gave the company a "hold" rating in a research report on Friday, April 11th. Mizuho lifted their target price on shares of Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Barclays raised their price target on shares of Humana from $270.00 to $322.00 and gave the company an "equal weight" rating in a research report on Friday, April 11th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Seventeen investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $284.90.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.